MUC1-specific immunotherapy

· Merck KGaA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MUC1-specific immunotherapy, covering 2017-02-28 to 2017-02-28. Get the full timeline:

Most recent: Clinical Trial Update: Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer [Phase 1]